Lung Screening and Early Stage Cancer Care Conference

Lung cancer, as with many cancers, often is not diagnosed until it has reached an advanced stage.  To increase survival rates, lung cancer screening has recently been approved as a tool that physicians can use to detect lung cancer at an earlier stage in a high risk population.  However, there is confusion among providers as to whether screening is worthwhile and what the exact criteria are for eligible patients.   

Lack of awareness of the latest guidelines in low dose CT screening and treatment of early stage lung cancer can contribute to poor outcomes including survival benefit.  In addition, a lung screening program is complex to establish and requires a multidisciplinary team of professionals working collaboratively to achieve quality outcomes.

Join this group of oncology specialists as they describe the current strategy for early detection and screening of lung cancer, review the treatment and clinical pathway algorhythm for early stage lung cancer and increase knowledge of support and survivorship resources for lung cancer patients and their caregivers.

1. Utilize AJCC or other appropriate staging in clinical practice, which includes the use of appropriate prognostic indicators and evidenced based national guidelines used in treatment planning.
2. List the major eligibility criteria for lung cancer screening
3. Discuss therapies and resources available for smoking cessation
4. List treatment strategies of early stage lung cancer
5. Discuss the use of survivorship care plans for lung cancer patients.
6. Gain an understanding of Nicotine Dependence
7. Discuss evidence-based tobacco cessation counseling techniques in combination with appropriate tobacco cessation pharmaceuticals in order to provide effective tobacco treatment
8. Discuss the components of a comprehensive approach to tobacco prevention & control
9. Discuss the principles of lung cancer screening
10. Discuss the benefits and harms of cancer screening
11. Review the result of the National Lung Cancer Screening Trial
12. Discuss the implications of the NLST on medical practice
13. List 3 criteria of lung cancer screening
14. Describe the shared decision making process
15. Define lungRADS in the context of the National Lung Cancer Screening Trial
16. Describe the rationale of lungRADs
17. Outline the categories of LungRADs and discuss the management strategies
18. Participants will be able to describe the purpose of the Rapid Access program
19. Participants will be able to list 2 ways to contact the Rapid Access program
20. Understand the importance of staging in the decision-making process for lung cancer management
21. Define and understand the rationale for the integral steps in the evaluation of suspected lung cancer
22. Review available, stage-specific treatment options for lung cancer
23. Understand the history and current role of surgery in the management of lung cancer patients
24. Review advancements in Radiation Oncology
25. Describe AAMC experience with treating medically-nonoperable early-stage lung cancer with Stereotactic Body Radiation Therapy (SBRT)
26. Radiation Oncology from patient perspective (ASTRO patient education video
27. Describe the two most common incidental findings on lung cancer screening imaging
28. Describe the initial evaluation for lung cancer screening imaging
29. Describe management and follow up of incidental findings for lung cancer screening imaging
30. Explain coronary artery calcification
31. Describe the treatment process for coronary artery calcification
32. Describe thoracic aortic aneurysm
33. Discuss pericardial effusion and pericardial calcification
34. Discuss the history of Cancer Survivorship
35. List essential components & process of Survivorship Care Plan
36. Discuss outcomes of cancer survivors

Registration Fee $25 - Master Card and Visa accepted.

Conference check-in and continental breakfast from 7:30-8:00 am

Conference starts at 8:00 am

The Anne Arundel Medical Center is accredited by MedChi, The Maryland State Medical Society to provide continuing medical education for physicians.

Nursing Continuing Education credits pending.

Course Directors:

Madelaine Binner, CRNP, DNP, Anne Arundel Medical Center DeCesaris Cancer Institute

Catherine Brady-Copertino, Executive Director, Anne Arundel Medical Center DeCesaris Cancer Institute

Stephen Cattaneo, MD, Thoracic Surgery, Anne Arundel Medical Center DeCesaris Cancer Institute

Joanne Ebner, Supervisor, Anne Arundel Medical Center Cancer Prevention

Peter Graze, MD, Hematology and Oncology, Anne Arundel Medical Center DeCesaris Cancer Institute

Maria Geronimo, Coordinator, Anne Arundel Medical Center Thoracic Oncology Program

Barry Meisenberg, MD, Hematology and Oncology, Medical Director of the Anne Arundel Medical Center DeCesaris Cancer Institute

Saturday, November 12, 2016